克莱姆生物
CLYM
9.82
-1.09
-9.99%
克莱姆生物
US · CLYM
#3610 按市值排名
上市于 2021
9.82
-1.09
-9.99%
实时 - 追踪5344个代码 - 心跳于404秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量增加了4家。
- 机构持股总比例上升了2.4个百分点。
机构持股
- 机构持股比例
- 109.79% +2.43pp
- 机构数量
- 132 +4
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund43.72%
VC/PE Fund34.61%
Hedge Fund29.89%
Individual/Insider1.65%
Public Company0.89%
Private Company0.45%
Insurance Company0.14%
主要股东 截至 2026-09-28
RA Capital Management, L.P.
21.83% · 12.54M 股
FMR
11.82% · 6.79M 股
Pontifax Venture Capital
9.06% · 5.21M 股
UBS Asset Management
5.93% · 3.40M 股
Braidwell LP
4.87% · 2.80M 股
Adage Capital Management, L.P.
4.36% · 2.51M 股
BlackRock
4.10% · 2.35M 股
T. Rowe Price Group, Inc.
3.70% · 2.13M 股
Cormorant Asset Management, LP
3.67% · 2.11M 股
Frontier Capital Management
3.38% · 1.94M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 38次买入 · 11次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| RA Capital Management, L.P. | -- | 21.83% |
| Stephen Thomas | Director | 0.81% |
| Aoife Brennan | Chief Executive Officer | 0.15% |
| Andrew Levin | Principal Financial Officer & Executive Chairman | 0.12% |
| Emily Pimblett | Principal Accounting Officer | 0.03% |
| Douglas Williams | Chair of Board | -- |
| Kimberlee Drapkin | Independent Director | -- |
| Cindy Driscoll | Officer | -- |
| Alexander Cumbo | Independent Director | -- |
| Susan Altschuller | Chief Financial Officer | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-27 | Andrew Levin | Principal Financial Officer & Executive Chairman | Derivative Exercise and Retained | +70,000 | $1.29–7.89 |
| 2026-09-14 | Stephen Thomas | Director | Automatic Disposition | -100,000 | $13.67 |
| 2026-06-28 | RA Capital Management, L.P. | -- | Other Derivative Acquisition | +70,284 | $13.36 |
| 2026-06-28 | Aoife Brennan | Chief Executive Officer | Derivative Exercise and Sale | -30,902 | $13.17 |
| 2026-06-28 | Aoife Brennan | Chief Executive Officer | Intent to Sell (Form 144) | -30,902 | $13.17 |
| 2026-06-26 | Aoife Brennan | Chief Executive Officer | Derivative Exercise and Retained | +37,848 | -- |
| 2026-06-04 | Douglas Williams | Chair of Board | Other Derivative Acquisition | +40,000 | $10.55 |
| 2026-06-04 | Kimberlee Drapkin | Independent Director | Other Derivative Acquisition | +40,000 | $10.55 |
| 2026-06-04 | RA Capital Management, L.P. | -- | Other Derivative Acquisition | +40,000 | $10.55 |
| 2026-06-04 | Andrew Levin | Principal Financial Officer & Executive Chairman | Other Derivative Acquisition | +40,000 | $10.55 |
| 2026-06-04 | Alexander Cumbo | Independent Director | Other Derivative Acquisition | +40,000 | $10.55 |
| 2026-06-04 | Stephen Thomas | Director | Other Derivative Acquisition | +40,000 | $10.55 |
| 2026-06-04 | Judith Dunn | Independent Director | Other Derivative Acquisition | +40,000 | $10.55 |
| 2026-04-28 | RA Capital Management, L.P. | -- | Other Derivative Acquisition | +2,106,000 | $0.00 |
| 2026-02-25 | Stephen Thomas | Director | Automatic Disposition | -50,000 | $7.00–7.01 |
| 2026-02-24 | Stephen Thomas | Director | Intent to Sell (Form 144) | -50,000 | $6.36 |
| 2026-02-12 | Stephen Thomas | Director | Automatic Disposition | -100,000 | $5.23–5.81 |
| 2026-02-11 | Stephen Thomas | Director | Intent to Sell (Form 144) | -100,000 | $5.56 |
| 2026-01-05 | Cindy Driscoll | Officer | Other Derivative Acquisition | +100,000 | $3.81 |
| 2026-01-05 | Aoife Brennan | Chief Executive Officer | Other Derivative Acquisition | +700,000 | $3.81 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
克莱姆生物 讨论区 0 条评论